- The Myeloma Beacon - https://myelomabeacon.org -
Elotuzumab (HuLuc63)
By: Jessica Langholtz; Published: December 3, 2009 @ 3:39 pm | Comments Disabled
| Brand Name: | |
| Generic Name: | elotuzumab |
| Code Name: | HuLuc63 |
| Company: | Facet Biotech/Bristol-Myers Squibb |
| FDA Clinical Phase: | 1/2 |
Description:
Elotuzumab (news [1]), a monoclonal antibody, selectively targets glycoproteins that are highly expressed on myeloma cells but not on healthy cells. In the presence of elotuzumab, myeloma cells undergo cell lysis and death. Clinical trials are currently underway to examine the activity of elotuzumab in patients with refractory or relapsed myeloma.
Clinical Trials:
For a list of clinical trials studying elotuzumab for the treatment of multiple myeloma, see ClinicalTrials.gov [2].
Web site for elotuzumab: http://www.facetbiotech.com/pipeline/product/elotuzumab/ [3]
Article printed from The Myeloma Beacon: https://myelomabeacon.org
URL to article: https://myelomabeacon.org/resources/2009/12/03/elotuzumab/
URLs in this post:
[1] news: https://myelomabeacon.org/tag/elotuzumab/
[2] ClinicalTrials.gov: http://clinicaltrials.gov/ct2/results?term=elotuzumab+myeloma
[3] http://www.facetbiotech.com/pipeline/product/elotuzumab/: http://www.facetbiotech.com/pipeline/product/elotuzumab/
Click here to print.
Copyright © The Beacon Foundation for Health. All rights reserved.